Featured Research
Interactive Model
Quickly generate a customized cost effectiveness analysis for implementing six-month drug-resistant TB treatments
BPaL Research: A Snapshot
Access to the latest treatment innovations is a human right.
We cannot afford to stop until our treatments are available to everyone who needs them. To date, new, six-month treatments for DR-TB have been producured to reach
TB Market Research
SLASH-TB
With this flexible model, developed by TB Alliance and Swiss Tropical and Public Health Institute, users can quickly generate a customized cost effectiveness analysis for implementing six-month drug-resistant TB treatments.
Learn More
Determining the Pediatric TB Burden
A major historical challenge in tackling childhood TB has been understanding the scope of the problem.
Learn More
The Global TB Market
Pathway to Patients: Charting the Dynamics of the Global TB Drug Market, was the first comprehensive analysis of how today's TB drugs reach patients on a global scale.
Learn More
Value Propositions of New Regimens
TB Alliance sought opinions on attributes that key decision-makers want in new regimens, including safety, efficacy, drug delivery, side effect profiles, and cost.
Learn More
Understanding Regimen Change
TB Alliance investigated health systems to understand the regimen change process, in order to accelerate and maximize the uptake of new products.
Learn More
Defining the Role of the Private Sector in Treatment
TB treatment is widely understood to be a public sector responsibility. However, our research found that in some countries the volume of TB drugs sold in the private sector is equal to or greater than the volume sold in the public sector.
Learn More